MS patients in rural areas are 17% less likely to receive DMTs than those in urban areas, a study of Alberta, Canada, ...

MS patients in the U.S. with Medicaid coverage have worse disease outcomes compared with those who have private insurance, a ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Ageing is associated with significant immunological changes that can influence both the progression of the disease and the ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis and visual deficits, ...

People with multiple sclerosis (MS) face a significantly higher ... MS medications can have adverse effects or be poorly tolerated, and many patients pursue alternative treatments, despite the ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing ...